0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.

      1 , ,
      The Journal of international medical research
      SAGE Publications

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The clinical impact of neutralizing antibodies (NAbs) on interferon beta (IFNbeta) efficacy was studied in three large patient cohorts comprising 6698 multiple sclerosis (MS) patients receiving IFNbeta-1b across North America, Europe, and Australia. In North America and Europe, NAb testing was generally undertaken because of a poor clinical response; in Australia, it was mandatory for every patient. Of the 6697 patients tested, 28.9% had at least one NAb titre > or = 20 neutralizing units (NU)/ml, 14.4% had NAb titres > or = 100 NU/ml and 7.7% had NAb titres > or = 400 NU/ml. The NAb-positive rate of 37.0% in Australia was significantly greater than those in North America (21.3%) and Europe (27.6%), and this was observed at every NAb titre level. Our results suggest that NAbs are not responsible for poor clinical responses and that NAb status is of little clinical value. These findings will need to be confirmed in a large independent study.

          Related collections

          Author and article information

          Journal
          J. Int. Med. Res.
          The Journal of international medical research
          SAGE Publications
          0300-0605
          0300-0605
          June 5 2007
          : 35
          : 2
          Affiliations
          [1 ] Department of Neurology, University of California, San Francisco 94143-0114, USA. douglas.goodin@ucsf.edu
          Article
          10.1177/147323000703500202
          17542405
          62ed890e-fc42-49fe-bc92-b6a0ec29f624
          History

          Comments

          Comment on this article